[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gastrointestinal-hemorrhage\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gastrointestinal-hemorrhage":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,50,80,105],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100605528","tips-for-complicated-portal-hypertension-related-to-porto-sinusoidal-vascular-disease-100605528",false,"NCT07163689","TIPS for Complicated Portal Hypertension Related to Porto-Sinusoidal Vascular Disease","TIPS for the Management of Complicated Portal Hypertension Related to Porto-Sinusoidal Vascular Disease","TIPS-PSVD","Inclusion Criteria:\n\n* PSVD group :\n* Patient with PSVD according VALDIG criteria\n* TIPS for digestive hemorrhage on portal hypertension\n* TIPS for refractory ascite\n* TIPS for portal vein thrombosis\n* Cirrhosis group with PH : (appaired by age, sexe, type of PH complications)\n* Confirmed cirrhosis with :\n* TIPS for digestive hemorrhage on portal hypertension\n* TIPS for refractory ascite\n* TIPS for portal vein thrombosis\n\nExclusion Criteria:\n\n* no PSVD confirmed diagnosis\n* Budd Chiari syndrome\n* Rendu Osler disease; Heart failure\n* Fontan; Sarcoïdosis\n* Schistosomiase\n* Congenitale liver fibrosis\n* Abernathy syndrome\n* Tumor infiltration by lymphoma\n* Bone graft","ALL","18 Years",{"count":20,"type":21},360,"ESTIMATED","OBSERVATIONAL","Porto-sinusoidal Vascular Disease (PSVD) is characterized by a portal hypertension (PH) without cirrhosis. This can induce PH complications, like digestive hemorrhage from esophageal or gastric varices, ascites, or even portal thrombosis. Due to the rarity of MVPS, the treatment of complications of portal hypertension is modeled on the methods used in cirrhotic portal hypertension with non-cardio-selective beta blockers, endoscopic ligations or diuretics in first line therapy, as proposed by the Baveno VII recommendations. In complicated or refractory forms of PH in PSVD, the place of TIPS is also discussed, as in the field of cirrhosis. However, the experience of TIPS in PSVD is limited, reported in case reports and small specifically dedicated series. No predictive factors for survival or recurrence and tolerance were well known. A larger study with control group is needed in order to better know the right time and the right indication for the use of TIPS in complicated PH PSVD-related.\n\nThe study will be retrospective, multicentric involving tertiary university French centers, expert in the management of TIPS. Patients white TIPS-PSVD will be compared with historical patients with TIPS-cirrhose, matched on age, sexe, indication of TIPS. The study will not comprise new intervention, only observational in a real life condition",[25,26,27,28,29,30],"TIPS","Portal Hypertension","Porto-Sinusoidal Vascular Disease","Refractory Ascite","Esophageal Varices","Gastrointestinal Hemorrhage",[25,32,33,34,35,36],"Portal hypertension","Porto-Sinusoidal Vascular disease","refractory ascite","esophageal varices","gastrointestinal hemorrhage","RECRUITING","2025-11-18",{"date":40,"type":41},"2025-11-19","ACTUAL",{"date":43,"type":41},"2025-05-16",{"date":45,"type":21},"2025-12",{"name":47,"class":48},"Centre Hospitalier Universitaire, Amiens","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":4},"100593932","phase-4-life-saving-treatment-with-dry-plasma-for-massive-bleeding-in-an-pre-hospital-setting-100593932","NCT07012863","Life-saving Treatment With Dry-plasma for Massive Bleeding in an Pre-hospital Setting","Life-saving Treatment With Dry-plasma for Massive Bleeding in an Pre-hospital Setting - - a Randomized Controlled Study","Inclusion Criteria:\n\n* Patients with clinical signs of bleeding which also triggers resuscitation with crisalloids acording to standard care protocol.\n\nExclusion Criteria:\n\n* Patients \\\u003C 18 years of age.\n* Patients who lack clinical signs of major bleeding.",{"count":58,"type":21},650,"INTERVENTIONAL",[61],"PHASE4","The overall goal of this clinical trial is to study how prehospital transfused dry plasma affect outcomes in terms of mortality as well as complications and coagulation status of patients in or about to develop bleeding shock.\n\nResearchers will compare dry plasma to standard care to see if dry plasma improves survival compared to crystalloid fluid in prehospital patients with heavy bleeding.",[64,65,30,66,67,68],"Bleeding","Aortic Rupture","Obstetric Bleeding","Blunt Injury","Penetrating Injury","NOT_YET_RECRUITING","2025-09-16",{"date":72,"type":41},"2025-09-17",{"date":74,"type":21},"2026-01-01",{"date":76,"type":21},"2027-09-30",{"name":78,"class":79},"Vastra Gotaland Region","OTHER_GOV",{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":90,"conditions":91,"keywords":93,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":4},"100583529","rapid-diagnostic-technology-for-augib-based-on-analysis-of-vocs-in-exhaled-breath-100583529","NCT06877507","Rapid Diagnostic Technology for AUGIB Based on Analysis of VOCs in Exhaled Breath","Rapid Diagnostic Technology for Acute Upper Gastrointestinal Bleeding Based on Analysis of Volatile Organic Compounds (VOCs) in Exhaled Breath","VOCsAUGIB","Inclusion Criteria:\n\n1. Age ≥18 years;\n2. Clinical suspicion of AUGIB (e.g., hematemesis, melena);\n3. Fasting ≥4 hours;\n4. Signed informed consent.\n\nExclusion Criteria:\n\n1. Severe pulmonary dysfunction or recent lung infection (within 1 week);\n2. Cardiac\u002Frenal failure or disseminated intravascular coagulation;\n3. Contraindications to endoscopy;\n4. High-risk conditions (e.g., massive ascites);\n5. Alcohol consumption within 24 hours;\n6. Pregnancy.",{"count":89,"type":21},200,"This study aims to develop a non-invasive and rapid diagnostic technology for acute upper gastrointestinal bleeding (AUGIB) by analyzing volatile organic compounds (VOCs) in exhaled breath. Clinically confirmed patients will be divided into three groups (no bleeding, minor bleeding, major bleeding) based on endoscopic findings. VOC profiles will be analyzed to construct a predictive model, validated for sensitivity and specificity (both targets ≥0.7). This approach addresses the limitations of endoscopy in emergency or resource-limited settings, improving diagnostic efficiency and reducing mortality.",[92,30],"Volatile Organic Compound",[92,94,95],"Acute Upper Gastrointestinal Bleeding","Exhaled Breath","2025-03-10",{"date":98,"type":41},"2025-03-14",{"date":100,"type":21},"2025-03-20",{"date":102,"type":21},"2025-07-20",{"name":104,"class":48},"Beijing 302 Hospital",{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":112,"sex":113,"minAge":114,"maxAge":115,"enrollmentInfo":116,"targetDuration":117,"studyType":22,"phases":4,"briefSummary":118,"conditions":119,"keywords":124,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":4},"100558591","diagnosis-and-clinical-presentation-of-iliac-graft-enteric-fistula-a-case-report-100558591","NCT06553105","Diagnosis and Clinical Presentation of Iliac Graft-Enteric Fistula: A Case Report","Department of Radiology, School of Medicine, 5th Azar Hospital, Gorgan, Golestan, Iran","Inclusion Criteria:\n\nn\u002Fa\n\nExclusion Criteria:\n\nn\u002Fa",true,"MALE","40 Years","50 Years",{"count":49,"type":21},"10 Days","Abstract\n\nIntroduction:\n\nAorto-enteric fistula (AEF) is a life-threatening complication arising from abnormal connections between the gastrointestinal tract and major arteries. One uncommon type, iliac artery-enteric fistula (IEF), can occur following vascular interventions such as arterial stent-graft placement.\n\nCase Presentation:\n\nWe report the case of a 47-year-old male presenting with hematemesis and abdominal pain, who was diagnosed with an iliac graft-enteric fistula. Timely recognition and management were crucial for a favorable outcome.\n\nClinical Discussion:\n\nDiagnosing AEFs remains challenging, requiring a multidisciplinary approach and high clinical suspicion. While computed tomography angiography (CTA) is commonly used for diagnosis, its sensitivity may be limited, emphasizing the importance of integrating clinical history and findings. Management strategies vary based on etiology and patient status, with surgery being pivotal.\n\nConclusion:\n\nAorto-enteric fistula, which can arise from a thrombosed graft, presents diagnostic challenges due to its rare formation. In patients with a history of vascular interventions and gastrointestinal bleeding, AEF should be considered. This case underscores the need for heightened awareness among healthcare professionals regarding AEF diagnosis and management to reduce severe morbidity, mortality, and prolonged hospital stays.",[120,121,122,30,123],"Case-report","Diagnosis","Digestive System Fistula","Iliac Graft-Enteric Fistula",[125],"case-report; CT scan; Diagnosis; Digestive System Fistula; Gastrointestinal Hemorrhage; Iliac Graft-Enteric Fistula.","2024-08-10",{"date":128,"type":41},"2024-08-14",{"date":130,"type":21},"2024-08-11",{"date":132,"type":21},"2024-08-13",{"name":134,"class":48},"Golestan University of Medical sciences"]